Rave-Fränk M
Department of radiotherapy radiooncology, Universität Göttingen, Robert Koch Strasse 40, 37075 Göttingen, Germany.
Cancer Radiother. 2017 Oct;21(6-7):554-556. doi: 10.1016/j.canrad.2017.08.105. Epub 2017 Aug 25.
Head and neck squamous cell carcinoma is one of the leading causes of cancer mortality worldwide. The prognosis for patients with head and neck squamous cell carcinoma has not substantially improved during the last decades, despite numerous advancements in treatment options. Reliable markers for early tumour detection and treatment response, which complement clinical examinations, imaging techniques, and biopsies would be extremely useful. One fairly new and promising method is the analysis of tumour-derived cell-free DNA (ctDNA) in the plasma of cancer patients. First data indicate that this method may assist, in the future, in the early detection of head and neck squamous cell carcinoma, the real-time monitoring of the disease course, the therapy response, and the prediction of prognosis with direct therapeutic implications by determining the best therapeutic modality for patient care.
头颈部鳞状细胞癌是全球癌症死亡的主要原因之一。尽管在治疗选择方面有诸多进展，但在过去几十年中，头颈部鳞状细胞癌患者的预后并未得到实质性改善。能够辅助临床检查、成像技术和活检的早期肿瘤检测及治疗反应的可靠标志物将非常有用。一种相当新且有前景的方法是分析癌症患者血浆中肿瘤来源的游离DNA（ctDNA）。初步数据表明，该方法未来可能有助于头颈部鳞状细胞癌的早期检测、疾病进程的实时监测、治疗反应以及通过确定最佳治疗方式为患者提供直接治疗意义的预后预测。
